** Shares of drug developer PepGen PEPG.O fall 27.4% to $3.40 premarket
** Co receives clinical hold notice from the US FDA regarding its mid-stage muscle disorder trial
** The FDA indicated they will provide an official clinical hold letter to the company within 30 days- PEPG
** The study was testing co's experimental drug, PGN-EDO51, in a 25-week clinical trial in patients with Duchenne muscular dystrophy
** Duchenne muscular dystrophy is a condition that causes skeletal and heart muscle weakness that quickly gets worse with time
** "We intend to work closely with the FDA to address their questions on our application to initiate CONNECT2 as expeditiously as possible," - PEPG
** Co says it continues to test PGN-EDO51 in the mid-stage trial in the 10 mg/kg group
** Up to last close, stock 31.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。